| Literature DB >> 30862253 |
Liliana Echavarria-Consuegra1, Jolanda M Smit1, Fulvio Reggiori2.
Abstract
Arboviruses that are transmitted to humans by mosquitoes represent one of the most important causes of febrile illness worldwide. In recent decades, we have witnessed a dramatic re-emergence of several mosquito-borne arboviruses, including dengue virus (DENV), West Nile virus (WNV), chikungunya virus (CHIKV) and Zika virus (ZIKV). DENV is currently the most common mosquito-borne arbovirus, with an estimated 390 million infections worldwide annually. Despite a global effort, no specific therapeutic strategies are available to combat the diseases caused by these viruses. Multiple cellular pathways modulate the outcome of infection by either promoting or hampering viral replication and/or pathogenesis, and autophagy appears to be one of them. Autophagy is a degradative pathway generally induced to counteract viral infection. Viruses, however, have evolved strategies to subvert this pathway and to hijack autophagy components for their own benefit. In this review, we will focus on the role of autophagy in mosquito-borne arboviruses with emphasis on DENV, CHIKV, WNV and ZIKV, due to their epidemiological importance and high disease burden.Entities:
Keywords: West Nile virus; alphaviruses; arboviruses; autophagy; dengue virus; flaviviruses
Mesh:
Year: 2019 PMID: 30862253 PMCID: PMC6451359 DOI: 10.1098/rsob.190009
Source DB: PubMed Journal: Open Biol ISSN: 2046-2441 Impact factor: 6.411
Figure 1.Flavivirus replication cycle. Flavivirus infection starts with the binding of the virion to cell receptors (step 1), which subsequently triggers the internalization of the viral particle via clathrin-mediated endocytosis (step 2). The acidic environment of late endosomes triggers the fusion of the virion with the limiting membrane of this organelle, resulting in the release of the genomic RNA into the cell cytoplasm (step 3). Translation of the viral RNA generates a polyprotein that is proteolytically cleaved into the non-structural (NS) and the structural proteins (step 4). NS proteins facilitate RNA replication leading to the formation of ssRNA− (green) and ssRNA+ (blue) transcripts (step 5). Progeny ssRNA+ is packaged by the capsid protein (C) to form the nucleocapsid. Viral assembly takes place in the ER (step 6), resulting in immature virions that are transported to the TGN through the secretory pathway, where furin-mediated cleavage of prM into M generates mature viral particles (step 7) that are released extracellularly by exocytosis (steps 8 and 9). The pr peptides dissociate from the virions once those are in the extracellular milieu.
Figure 2.CHIKV replication cycle. CHIKV infection is initiated by the binding of the viral particle to cell receptors (step 1), which triggers the internalization of the virion via clathrin-mediated endocytosis (step 2). Subsequent fusion of the viral particle with the early endosome limiting membrane leads to the cytoplasmic release of the genomic RNA release (step 3). Genomic RNA is initially translated from the 5′-ORF into the viral replicase (P1234) (step 4), which replicate the ssRNA− (green) and the ssRNA− (blue) (step 5). The viral replicase also replicates the subgenomic RNA from the 3′-ORF (step 6), which serves as the template for the translation of structural proteins (step 7). The structural pE2 and E1 proteins are inserted into the ER and they are first processed in this organelle and then in the TGN, where furin-mediated proteolytical cleavage generates mature E2–E1 heterodimers that are exported to the plasma membrane (step 8). Genomic RNA is packaged by the C protein (step 9) and by interacting with the E2–E1 heterodimers, initiate the budding of the viral particle from the plasma membrane (step 10) to produce progeny virions (step 11).
Key proteins involved in autophagosome formation and its fusion with lysosomes in mammalian cells.
| step of autophagy | functional cluster | components | |
|---|---|---|---|
| initiation | ULK kinase complex | ULK1-2 | |
| autophagy-specific | VPS34 | ||
| ATG9A trafficking system | WIPI1-4 | ||
| elongation | ubiquitin-like conjugation systems | ATG12 conjugation system | ATG7 |
| LC3 conjugation system | ATG4A-D | ||
| fusion | CCZ1-MON1A | ||
| RAB7 | |||
| HOPS | VPS11/VPS16/VPS18/VPS33A | ||
| SNAREs | STX17/VAMP8/ | ||
| cargo degradation | lysosomal enzymes | cathepsin B, L, D and other hydrolases | |
Figure 3.Schematic representation of the key steps of the autophagy process. Autophagy initiation is under the control of several regulatory signals such as ER stress, ROS production, AMPK or mTORC1 signalling, and the presence of microorganisms. Autophagy begins with the formation of a small cistern, the phagophore, which elongates and sequesters cytoplasmic components such as protein aggregates and organelles. Closure of the phagophore generates a double-membrane vesicle-denominated autophagosome. Subsequent fusion of the autophagosome with lysosomes results in the formation of autolysosomes, where lysosomal hydrolases degrade the cargo contained in the interior of these vesicles (see text for details).
Summary of the literature describing an antiviral or proviral role of autophagy or ATG proteins over the course of specific flavivirus infections.
| ( | |||
|---|---|---|---|
| (i) ( | |||
| WT MEFs | rapamycin treatment | proviral | [ |
| proviral | |||
| Huh7 | rapamycin treatment | proviral | |
| Huh7 | stable p62 overexpression | antiviral (p62) | [ |
| Huh7 | 3-MA treatment | proviral | [ |
| HepG2 | AMPK | proviral | [ |
| BHK-21 | spautin-1 treatment | proviral (supports viral maturation) | [ |
| MDCK | Wortmannin treatment | proviral | [ |
| KU812 | Atg4BC74A overexpression | proviral | [ |
| A549 | rapamycin treatment | no effect | [ |
| THP-1 | rapamycin treatment | antiviral | |
| U937 (ADE conditions) | rapamycin treatment | antiviral (mild effect) | [ |
| HepG2 (DENV-2) | rapamycin treatment | proviral | [ |
| 3-MA treatment | |||
| HepG2 (DENV-3) | rapamycin treatment | proviral | [ |
| 3-MA treatment | |||
| Huh7 | ATG5 and ATG9 siRNA | proviral (autophagy participates in virus spread in co-cultured cells) | [ |
| proviral | [ | ||
| Huh7 | IRE1 | proviral (indirect) | [ |
| HepG2 | AUP1 siRNA | proviral (AUP1) | [ |
| K562 (ADE conditions) | rapamycin treatment | proviral | [ |
| HBMEC | FAM134B siRNA | antiviral (FAM134B, reticulophagy) | [ |
| HeLa | CRISPR-Cas9 knockout of ATG9A, VPS34 and LC3B | proviral | [ |
| (ii) ( | |||
| suckling mice | rapamycin treatment | proviral | [ |
| 3-MA treatment | no effect | ||
| suckling mice | SP600125 treatment | proviral | [ |
aMeasured by assessing viral titres, percentage of infection, extracellular or intracellular RNA.
Summary of the literature describing an antiviral or proviral role of autophagy or ATG proteins over the course of CHIKV infection.
| ( | |||
|---|---|---|---|
| (i) ( | |||
| HEK.293 | rapamycin treatment | proviral | [ |
| — | antiviral | [ | |
| HeLa | TAT-BECN1 peptide | antiviral | [ |
| HeLa | rapamycin treatment | proviral | [ |
| p62 siRNA | antiviral | ||
| HLFs | NDP52 siRNA | proviral (NDP52) | |
| p62 siRNA | antiviral (p62) | ||
| WT MEFs | NDP52 siRNA | no effect | |
| — | antiviral | ||
| (ii) ( | |||
| — | no effect on viral titres but increased pathogenesis (lethality) | [ | |
aMeasured by assessing viral titres, percentage of infection, extracellular or intracellular RNA.